A Review of KSHV: Lifecycle, Tumorigenesis, Immune Evasion and Therapeutic Strategies.
- 1School of Medicine, Shihezi University, Shihezi 832002, China.
Abstract
Kaposi's sarcoma-associated herpesvirus (KSHV) is an important human gamma-herpesvirus, particularly with a significant incidence rate among AIDS patients and other immunosuppressed populations. This review introduces the basic virological characteristics of KSHV and elucidates the core molecular mechanisms underlying KSHV tumorigenesis. Clinical management primarily focuses on KSHV-related diseases, utilizing antiretroviral therapy, chemotherapy, radiotherapy, and therapies targeting specific targets. However, there still lack of specific anti-KSHV drugs in terms of treatment. Current research is increasingly directed toward novel therapeutic strategies, including those that sustain viral latency or promote lytic reactivation, alongside antigen-based immunotherapeutic approaches. Despite significant breakthroughs in research, the precise regulatory network of KSHV latent infection, the complex interactions between the virus and the host microenvironment (especially inflammatory and immune cells), as well as the development of highly effective and low-toxicity specific antiviral drugs, remain major challenges for the future. A deep understanding of the pathogenic mechanisms of KSHV will lay a solid foundation for the development of more effective prevention, diagnosis, and treatment methods.
Related
- Editorial: Immunology of human fungal pathogens: host-pathogen interactions, immune evasion, and therapeutic strategies
- Residual atherosclerotic cardiovascular disease risk in statin-treated patients: mechanisms, therapeutic strategies, and future directions—a scoping review
- Microneedles for Chronic Refractory Wounds: A Review of Dynamic Regulation Strategies and Therapeutic Applications.
- Neurogenic thoracic outlet syndrome: a review of diagnostic and therapeutic strategies.
- Bias Mitigation Across the Healthcare Artificial Intelligence Lifecycle: A Structured Narrative Review
BibTeX
@article{zhuo2026review,
title = {{A Review of KSHV: Lifecycle, Tumorigenesis, Immune Evasion and Therapeutic Strategies.}},
author = {Chaoran Zhuo and Dongdong Cao and Fangling Li},
journal = {Viruses},
year = {2026},
month = sep,
doi = {10.3390/v18101053},
url = {https://europepmc.org/article/MED/42943973},
note = {CC BY},
}
RIS
TY - JOUR
TI - A Review of KSHV: Lifecycle, Tumorigenesis, Immune Evasion and Therapeutic Strategies.
AU - Chaoran Zhuo
AU - Dongdong Cao
AU - Fangling Li
PY - 2026
DA - 2026/09/23
JO - Viruses
DO - 10.3390/v18101053
UR - https://europepmc.org/article/MED/42943973
AB - Kaposi's sarcoma-associated herpesvirus (KSHV) is an important human gamma-herpesvirus, particularly with a significant incidence rate among AIDS patients and other immunosuppressed populations. This review introduces the basic virological characteristics of KSHV and elucidates the core molecular mechanisms underlying KSHV tumorigenesis. Clinical management primarily focuses on KSHV-related diseases, utilizing antiretroviral therapy, chemotherapy, radiotherapy, and therapies targeting specific targets. However, there still lack of specific anti-KSHV drugs in terms of treatment. Current research is increasingly directed toward novel therapeutic strategies, including those that sustain viral latency or promote lytic reactivation, alongside antigen-based immunotherapeutic approaches. Despite significant breakthroughs in research, the precise regulatory network of KSHV latent infection, the complex interactions between the virus and the host microenvironment (especially inflammatory and immune cells), as well as the development of highly effective and low-toxicity specific antiviral drugs, remain major challenges for the future. A deep understanding of the pathogenic mechanisms of KSHV will lay a solid foundation for the development of more effective prevention, diagnosis, and treatment methods.
SN - 1999-4915
ER -